Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 2
2014 3
2015 3
2016 1
2018 4
2019 1
2021 4
2022 3
2023 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy and toll-like receptor agonists.
Marabelle A, Filatenkov A, Sagiv-Barfi I, Kohrt H. Marabelle A, et al. Among authors: sagiv barfi i. Semin Radiat Oncol. 2015 Jan;25(1):34-9. doi: 10.1016/j.semradonc.2014.07.006. Semin Radiat Oncol. 2015. PMID: 25481264 Review.
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Kohrt HE, et al. Among authors: sagiv barfi i. Blood. 2014 Mar 20;123(12):1957-60. doi: 10.1182/blood-2014-01-547869. Blood. 2014. PMID: 24652965 Free PMC article. No abstract available.
Intratumoral immunotherapy relies on B and T cell collaboration.
Sagiv-Barfi I, Czerwinski DK, Shree T, Lohmeyer JJK, Levy R. Sagiv-Barfi I, et al. Sci Immunol. 2022 May 27;7(71):eabn5859. doi: 10.1126/sciimmunol.abn5859. Epub 2022 May 27. Sci Immunol. 2022. PMID: 35622903 Free PMC article.
Targeting CD137 enhances the efficacy of cetuximab.
Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R. Kohrt HE, et al. Among authors: sagiv barfi i. J Clin Invest. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129689. Epub 2019 Jun 3. J Clin Invest. 2019. PMID: 31157621 Free PMC article. No abstract available.
Eradication of spontaneous malignancy by local immunotherapy.
Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R. Sagiv-Barfi I, et al. Sci Transl Med. 2018 Jan 31;10(426):eaan4488. doi: 10.1126/scitranslmed.aan4488. Sci Transl Med. 2018. PMID: 29386357 Free PMC article.
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.
Kooreman NG, Kim Y, de Almeida PE, Termglinchan V, Diecke S, Shao NY, Wei TT, Yi H, Dey D, Nelakanti R, Brouwer TP, Paik DT, Sagiv-Barfi I, Han A, Quax PHA, Hamming JF, Levy R, Davis MM, Wu JC. Kooreman NG, et al. Among authors: sagiv barfi i. Cell Stem Cell. 2018 Apr 5;22(4):501-513.e7. doi: 10.1016/j.stem.2018.01.016. Epub 2018 Feb 15. Cell Stem Cell. 2018. PMID: 29456158 Free PMC article.
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research.
Alspach E, Chow RD, Demehri S, Guerriero JL, Gujar S, Hartmann FJ, Helmink BA, Hudson WH, Ho WJ, Ma L, Maier BB, Maltez VI, Miller BC, Moran AE, Parry EM, Pillai PS, Rafiq S, Reina-Campos M, Rosato PC, Rudqvist NP, Ruhland MK, Sagiv-Barfi I, Sahu AD, Samstein RM, Schürch CM, Sen DR, Thommen DS, Wolf Y, Zappasodi R. Alspach E, et al. Among authors: sagiv barfi i. Cancer Immunol Res. 2021 Nov;9(11):1245-1251. doi: 10.1158/2326-6066.CIR-21-0519. Epub 2021 Sep 20. Cancer Immunol Res. 2021. PMID: 34544686 Free PMC article.
21 results